ConferenceFrontiers in Immunology · January 1, 2023
Rhesus macaques (RMs) are a common pre-clinical model used to test HIV vaccine efficacy and passive immunization strategies. Yet, it remains unclear to what extent the Fc-Fc receptor (FcR) interactions impacting antiviral activities of antibodies in RMs re ...
Full textCite
ConferenceMicroorganisms · November 4, 2020
Antibody responses that correlated with reduced risk of HIV acquisition in the RV144 efficacy trial were assessed in healthy African volunteers who had been primed three times with HIV-DNA (subtype A, B, C) and then randomized into two groups; group 1 was ...
Full textLink to itemCite
ConferenceJ Virol · October 14, 2020
The "shock-and-kill" human immunodeficiency virus type 1 (HIV-1) cure strategy involves latency reversal followed by immune-mediated clearance of infected cells. We have previously shown that activation of the noncanonical NF-κB pathway using an inhibitor ...
Full textLink to itemCite
ConferenceJ Virol · February 1, 2019
The use of heterologous immunization regimens and improved vector systems has led to increases in immunogenicity of HIV-1 vaccine candidates in nonhuman primates. In order to resolve interrelations between different delivery modalities, three different pox ...
Full textLink to itemCite
ConferenceJAIDS Journal of Acquired Immune Deficiency Syndromes · April 2018
Anti-HIV antibody function is not limited to capturing free virus but also includes the recognition of HIV-1 infected cells. Both neutralizing and nonneutralizing antibody responses recognizing HIV-1 envelope epitopes expressed on the cellular memb ...
Full textCite
ConferenceFASEB Journal · 1998
Several multiply HIV-exposed, uninfected cohorts were studied for evidence of correlates of protective immunity. This uninfected high risk population was comprised of the IV drug-sharing and/or sexual partners of infected individuals. Genotyping of cells f ...
Cite
